11 #AHA24 ScientificSessions.org Learn strategies to better manage VTE in your practice with our on-demand digital learning activities. These activities are supported by a medical education grant from the Bristol Myers Squibb and Pfizer Alliance. PAID ADVERTISEMENT Advancing Management and Care in Venous Thromboembolism (VTE) QA& Annual Dr. Nanette K. Wenger Research Goes Red® Award for Best Scientific Publication on Cardiovascular Disease and Stroke in Women 9:45-11 a.m. | Saturday, Nov. 16 S100A UPCOMING SESSION Shah Research Goes Red recognition Silvi Shah, MD, MS, will receive this year’s award honoring Dr. Nanette K. Wenger. In 2021, the American Heart Association established the Dr. Nanette K. Wenger Research Goes Red Award. The accolade, sponsored by the AHA’s Research Goes Red initiative, recognizes the best scientific article on cardiovascular disease and stroke in women that was published in an AHA journal. Silvi Shah, MD, MS, is this year’s recipient of the award, and she will present her article Saturday morning at Scientific Sessions. Shah is an associate professor in the Division of Nephrology and Hypertension at the University of Cincinnati College of Medicine. Scientific Sessions Daily News spoke with Shah to learn more about her background, research and awardwinning article, “Sex Differences in Cardiovascular Outcomes in Patients With Kidney Failure,” which was published in May in the Journal of the American Heart Association. The study was funded by a K23 career development award that Shah received from the National Institutes of Health. Q Congratulations on winning the Dr. Nanette K. Wenger Research Goes Red Award. What is the theme of your article, and what are some of the highlights that you will present during the session? Shah: Our study looked at sex differences in cardiovascular outcomes in patients with kidney failure who were receiving dialysis. Interestingly, we show that women, as compared to men, have a 14% higher risk of cardiovascular events, 16% higher risk of heart failure, 31% higher risk of stroke and no difference in risk of acute coronary syndrome. Our study is one of the first studies, to the best of our knowledge, to examine and report a higher risk of cardiovascular events in women among patients with kidney failure. Q Was there a specific experience or encounter that drove this investigation? Shah: Cardiovascular disease remains the leading cause of death in patients with kidney disease. Also, the risk of cardiovascular events is 10 to 20 times higher in patients with kidney failure as compared to the general population. I saw a 50-year-old female patient who had a history of kidney failure and was receiving hemodialysis at Cleveland Clinic. While evaluating her for possible transplantation, she asked how her cardiovascular risk differs by sex. Although sex differences in cardiovascular disease are well described in the general population, little is known about this among patients with kidney failure, which drove the initiation of the study. Q What is the importance of this research? Shah: Cardiovascular disease is the leading cause of death in women, and critical knowledge gaps continue to exist about women’s cardiovascular health, including sex differences in cardiovascular disease burden among patients receiving dialysis. Due to the high morbidity and mortality of cardiovascular disease in women and the paucity of data, the Research Goes Red initiative is essential.
RkJQdWJsaXNoZXIy MjI2NjI=